Abstract
Since the discovery of the aflatoxins in 1960, much effort has been made by research laboratories to investigate the association between exposure to naturally occurring carcinogens and long-term adverse health effects in people. In the case of aflatoxin B1, these health consequences range from acute hepatic liver toxicities to liver cancer. During the ensuing years, the vast majority of the mechanistic biochemical studies inquiring into the mode of action of naturally occurring chemical carcinogens have been carried out using aflatoxin Bl. In fact, the aflatoxins are among the few ubiquitous and structurally identified environmental carcinogens for which quantitative estimates of human exposure have been systematically sought and risk assessments attempted. However, in the past 10 years compounds such as sterigmatocystin, cycasin, the family of pyrrolizidine alkaloids, and especially safrole and estragole have been more extensively probed. Stimulus for this research has undoubtedly been generated by the hypothesis that prevention of dietary exposure to naturally occurring plant and fungal carcinogens will improve the general health status of a population. Since it is almost axiomatic that the development of human cancer can be modulated by many factors both biological and chemical in nature, and because initiation, promotion, and progression-like events are required prior to the clinical diagnosis of a tumor, no one agent can be responsible for, or present at all the critical stages during the growth of a tumor. Therefore, the systematic investigation of the biological consequences of exposure to dietary carcinogens will help to develop appropriate cancer prevention strategies.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Autrup H, Bradley KA, Shamsuddin AKM, Wakhisi J, Wasunna A (1983) Detection of putative adduct with fluorescence characteristics identical to 2,3-dihydro-2-(7’-guanyl)- 3-hydroxyaflatoxin B1 in human urine collected in Murang’a district, Kenya. Carcinogenesis 4 (9): 1193–1195
Autrup H, Seremet T, Wakhisi J, Wasunna A (1987) Aflatoxin exposure measured by urinary excretion of aflatoxin Bt-guanine adduct and hepatitis B virus infection in areas with different liver cancer incidence in Kenya. Cancer Res 47: 3430–3433
Bennett RA, Essigmann JM, Wogan GN (1981) Excretion of an aflatoxin-guanine adduct in urine of aflatoxin B1-treated rats. Cancer Res 41: 650–654
Bishop JM (1985) Viral oncogenes. Cell 42: 23–38
Bulatao-Jayme J, Almero EM, Castro CA, Jardeleza TR, Salamat L (1982) A case-control dietary study of primary liver cancer risk from aflatoxin exposure. Int J Epidemiol 11: 112–119
Busby WF, Wogan GN (1984) Aflatoxins. In: Searle CE (ed) Chemical carcinogens, 2nd edn. American Chemical Society, Washington DC, pp 945–1136
Cabral JRP, Neal GE (1983) The inhibitory effects of ethoxyquin on the carcinogenic action of aflatoxin B1 in rats. Cancer Lett 9: 125–132
Campbell AA, Whitaker TB, Pohland AE, Dickens JW, Park DL (1986) Sampling, sample preparation, and sampling plans for foodstuffs for mycotoxion analysis. Pure and Applied Chemistry 58: 305–314
Campbell TC, Caedo JP, Bulatao-Jayme J, Salamat L, Engel RW (1970) Aflatoxin M1 in human urine. Nature 227: 403–404
Candrian U, Luthy J, Schlatter C (1985) In vivo covalent binding of retronecine-labelled [3H] senecionine to DNA of rat liver, lung and kidney. Chem Biol Interact 54: 57–69
Croy RG, Wogan GN (1981) Temporal patterns of covalent DNA adducts in rat liver after single and multiple doses of aflatoxin B1. Cancer Res 41: 197–203
Croy RG, Essigmann JM, Reinhold VN, Wogan GN (1978) Identification of the principle aflatoxin Bl-DNA adduct formed in vivo in rat liver. Proc Natl Acad Sci USA 75: 1745–1749
Cullen JM, Ruebner BH, Hseih LS, Hyde DM, Hseih DP (1987) Carcinogenicity of dietary aflatoxin Ml in male Fischer rats compared to aflatoxin Bl. Cancer Res 47: 1913–1917
DeLong MJ, Prochaska HJ, Talalay P (1983) Substituted phenols as inducers of enzymes which inactivate electrophilic compounds. In: McBrien DC, Slater TF (eds) Protective agents in human and experimental cancer. Academic, London, pp 175–196
Donahue PR, Essigmann JM, Wogan GN (1982) Alfatoxin-DNA adducts: detection in urine as a dosimeter of exposure. Banbury Report 13: 221–229
Essigmann JM, Croy RG, Nadzan AM, Busby WF Jr, Reinhold VN, Buchi G, Wogan GN (1977) Structural identification of the major DNA adduct formed by aflatoxin Bl in vitro. Proc Natl Acad Sci USA 74: 1870–1874
Essigmann JM, Barker LJ, Fowler KW, Francisco MA, Reinhold VN, Wogan GN (1979) Sterigmatocystin-DNA interactions: identification of a major adduct formed after metabolic activation in vitro. Proc Natl Acad Sci USA 76: 179–183
Fennell TR, Wiseman RW, Miller JA, Miller EC (1985) Major role of hepatic sulfotransferase activity in the metabolic activation, DNA adduct formation, and carcinogenicity of 1’-hydroxy-2’,3’-dehydroestragole in infant male C57BL/6J × C3H/HeJ F1 mice. Cancer Res 45: 5310–5320
Fennell TR, Juhl U, Miller EC, Miller J A (1986) Identification and quantitation of hepatic DNA adducts formed in B6C3F1 mice from l’-hydroxy-2’,3’-dehydroestragole: comparison of the adducts detected with the r-3H-labelled carcinogen and by 32P- postlabelling. Carcinogenesis 7: 1881–1887
Goeger DE, Shelton DW, Hendricks JD, Bailey GS (1986) Mechanisms of anti- carcinogenesis by indole-3-carbinol: effect on the distribution and metabolism of aflatoxin Bl in rainbow trout. Carcinogenesis 7: 2025–2031
Groopman JD, Kensler TW (1987) The use of monoclonal antibody affinity columns for assessing DNA damage and repair following exposure to aflatoxin Bl. Pharmacol Ther 34: 321–334
Groopman JD, Busby WF Jr, Wogan GN (1980) Nuclear distribution of aflatoxin Bl and its interaction with histones in rat liver in vivo. Cancer Res 40: 4343–4351
Groopman JD, Haugen A, Goodrich GR, Harris CC (1982) Quantitation of aflatoxin Bl modified DNA using monoclonal antibodies. Cancer Res 42: 3120–3124
roopman JD, Trudel LJ, Donahue PR, Rothstein A, Wogan GN (1984) High affinity monoclonal antibodies for aflatoxins and their application to solid phase immunoassay. Proc Natl Acad Sci USA 81: 7728–7731
Groopman JD, Donahue PR, Zhu J, Chen J, Wogan GN (1985) Aflatoxin metabolism in humans: detection of metabolites and nucleic acid adducts in urine by affinity chromatography. Proc Natl Acad Sci USA 82: 6492–6497
Groopman JD, Busby WF, Donahue PR, Wogan GN (1986) Aflatoxins as risk factors for liver cancer: an application of monoclonal antibodies to monitor human exposure. In: Harris CC (ed) Biochemical and molecular epidemiology of cancer. Liss, New York, pp 233–256
Groopman JD, Donahue PR, Zhu J, Chen J, Wogan GN (1987) Temporal patterns of aflatoxin metabolites in urine of people living in Guangxi Province, P.R.C. Proc Am Assoc Cancer Res 28: 36
Gurtoo HL, Dahms RP, Paigen B (1975) Metabolic activation of aflatoxins related to their mutagenicity. Biochem Biophys Res Comm 61. 735–742
Gurtoo HL, Koser PL, Bansal SK, Fox HW, Sharma SD, Mulhern AI, Pavelic ZP (1985) Inhibition of aflatoxin Bl-hepatocarcinogenesis in rats by B-napthoflavone. Carcinogenesis 6: 675–678
Haugen A, Groopman JD, Hsu IC, Goodrich GR, Wogan GN, Harris CC (1981) Monoclonal antibody to aflatoxin B1 modified DNA detected by enzyme immunoassay. Proc Natl Acad Sci USA 78: 4124–4127
Hertzog PJ, Lindsay Smith JR, Garner RC (1982) Production of monoclonal antibodies to guanine imidazole ring-opened aflatoxin Bl-DNA, the persistent DNA adduct in vivo. Carcinogenesis 3: 723–725
Hoffmann GR, Morgan RW (1984) Review: putative mutagens and carcinogens in foods. V. Cycad azoxyglycosides. Environ Mutagen 6: 103–116
Jeffrey AM (1985) DNA modification by chemical carcinogens. Pharmacol Ther 28: 237–272
Kensler TW, Enger PA, Trush MA, Bueding E, Groopman JD (1985) Modification of aflatoxin B1 binding to DNA in vivo in rats fed phenolic antioxidants, ethoxyquin and a dithiothione. Carcinogenesis 6: 759–763
Kensler TW, Egner PA, Davidson NE, Roebuck BD, Pikul A, Groopman JD (1986) Modulation of aflatoxin metabolism, aflatoxin N7-guanine formation and hepatic tumorigenesis in rats fed ethoxyquin: role of induction of glutathione S-transferases. Cancer Res 46: 3924–3931
Lin JK, Miller JA, Miller EC (1977) 2,3-Dihydro-2(guan-7-yl)-3-hydroxy-aflatoxin B1, a major acid hydrolysis product of aflatoxin Bl-DNA or -ribosomal RNA adducts formed in hepatic microsome mediated reactions in rat liver in vivo. Cancer Res 37: 4430–4438
Linsell CA, Peers FG (1977) Aflatoxin and liver cancer. Trans R Soc Trop Med Hyg 71: 471–473
Mandel HG, Manson MM, Judah DJ, Simpson JL, Green JA, Forrester LM, Wolf CR, Neal GE (1987) Metabolic basis for the protective effect of the antioxidant ethoxyquin on aflatoxin Bl hepatocarcinogenesis in the rat. Cancer Res 47: 5218–5223
McLean AEM, Marshall A (1971) Reduced carcinogenic effects of aflatoxin in rats given phenobarbitone. Br J Exp Pathol 52: 322–329
McMahon G, Hanson L, Lee J J, Wogan GN (1986) Identification of an activated c-Ki-ras oncogene in rat liver tumors induced by aflatoxin B1. Proc Natl Acad Sci USA 83: 9418–9422
McMahon G, Davis E, Wogan GN (1987) Characterization of c-Ki-ras oncogene alleles by direct sequencing of enzymatically amplified DNA from carcinogen-induced tumors. Proc Natl Acad Sci USA 84: 4974–4978
Miller EC, Miller J A (1986) Carcinogens and mutagens that may occur in foods. Cancer 58: 1795–1803
Miller EC, Swanson AB, Phillips DH, Fletcher TL, Liem A, Miller J A (1983) Structure-activity studies of the carcinogenicities in the mouse and rat of some naturally occurring and synthetic alkenylbenzene derivatives related to safrole and estragole. Cancer Res 43: 1124–1134
Miller J A, Miller EC (1983) The metabolic activation and nucleic acid adducts of naturally-occurring carcinogens: recent results with ethyl carbamate and the spice flavors safrole and estragóle. Br J Cancer 48: 1–15
Morgan RW, Hoffmann GR (1983) Cycasin and its mutagenic metabolites. Mutat Res 114: 19–58
National Cancer Office of the Ministry of Public Health, P.R.C. (1980) Studies on mortality rates of cancer in China. People’s Publishing House, Beijing
Peers F, Bosch X, Kaldor J, Linsell A, Pluijmen M (1987) Aflatoxin exposure, hepatitis B virus infection and liver cancer in Swaziland. Int J Cancer 39: 545–553
Pestka JJ, Chu FS (1982) Reactivity of aflatoxin B2a antibody with aflatoxin Bl-modified DNA and related metabolites. Appl Environ Microbiol 44: 1159–1165
Petry TW, Bowden GT, Huxtable RJ, Sipes IG (1984) Characterization of hepatic DNA damage induced in rats by the pyrrolizidine alkaloid monocrotaline. Cancer Res 44: 1505–1509
Phillips DH, Miller J A, Miller EC, Adams B (1981) N2 atom of guanine and N6 atom of adenine residues as sites for covalent binding of metabolically activated 1’-hydroxysafrole to mouse liver DNA in vivo. Cancer Res 41: 2664–2671
Phillips DH, Reddy MV, Randerath K (1984) 32P-Postlabelling analysis of DNA adducts formed in the livers of animals treated with safrole, estragole and other naturally-occurring alkenylbenzenes. II. Newborn male B6C3F1 mice. Carcinogenesis 5: 1623–1628
Randerath K, Haglund RE, Phillips DH, Reddy MV (1984) 32P-Post-labelling analysis of DNA adducts formed in the livers of animals treated with safrole, estragole and other naturally-occurring alkenyl-benzenes. I. Adult female CD-1 mice. Carcinogenesis 5: 1613–1622
Reddy MY, Irvin TR, Randerath K (1985) Formation and persistence of sterigmatocystin-DNA adducts in rat liver determined via 32P-postlabeling analysis. Mutat Res 152: 85–96
Robertson KA (1982) Alkylation of N2 in deoxyguanosine by dehydroretronecine, a carcinogenic metabolite of the pyrrolizidine alkaloid monocrotaline. Cancer Res 42: 8–14
Robins DJ (1982) The pyrrolizidine alkaloids. Fortschr Chem Org Naturst 41: 115–203
Sabbioni G, Skipper P, Buchi G, Tannenbaum SR (1987) Isolation and characterization of the major serum albumin adduct formed by aflatoxin B1 in vivo in rats. Carcinogenesis 8: 819–824
Schoental R (1982) Health hazards of pyrrolizidine alkaloids: a short review. Toxicol Lett 10: 323–326
Shamsuddin AM, Harris CC, Hinzman MJ (1987) Localization of aflatoxin B1-nucleic acid adducts in mitochondria and nuclei. Carcinogenesis 8: 109–114
Shank RC, Magee PN (1967) Similarities between the biochemical actions of cycasin and dimethyluitrosamine. Biochem J 105: 521–527
Stoloff L (1980) Aflatoxin control — past and present. J Assoc Off Anal Chem 63: 1067–1073
Sun TT, Chu YY (1984) Carcinogenesis and prevention strategy of liver cancer in areas of prevalence. J Cell Physiol [Suppl i] 3: 39–44
Sun TT, Chu YR, Hsia CC, Wei YP, Wu SM (1986) Strategies and current trends of etiologic prevention of liver cancer. In: Harris CC (ed) Biochemical and molecular epidemiology. Liss, New York, pp 283–292
Van Rensburg SJ, Cook-Mozaffari P, Van Schalkwyk DJ, Van der Watt JJ, Vincent TJ, Purchase IF (1985) Hepatocellular carcinoma and dietary aflatoxin in Mozambique and Transkei. Br J Cancer 51: 713–726
Weinberg RA (1985) The action of oncogenes in the cytoplasm and nucleus. Science 230: 770–776
Wild CP, Umbenhauer D, Chapot B, Montesano R (1986) Monitoring of individual human exposure to aflatoxins (AF) and N~nitrosamines ( NNO) by immunoassays. J Cell Biochem 30: 171–179
Wild CP, Garner RG, Montesano R, Tursi F (1986) Aflatoxin B1 binding to plasma albumin and liver DNA upon chronic administration to rats. Carcinogenesis 7: 853–858
Williams GM, Tanaka T, Maeura Y (1986) Dose-dependent inhibition of aflatoxin B1 induced hepatocarcinogenesis by the phenolic antioxidants, butylated hydroxytoluene and butylated hydroxyanisole. Carcinogenesis 7: 1043–1050
Wiseman RW, Fennell TR, Miller JA, Miller EC (1985) Further characterization of the DNA adducts formed by electrophilic esters of the hepatocarcinogens 1’-hydroxysafrole and l’-hydroxyestragole in vitro and in mouse liver in vivo, including new adducts at C-8 and N-7 of guanine residues. Cancer Res 45: 3096–3105
Wiseman RW, Stowers SJ, Miller EC, Anderson MW, Miller J A (1986) Activating mutations of the c-Ha-ras1 protooncogene in chemically induced hepatomas of the male B6C3 F1 mouse. Proc Natl Acad Sci USA 83: 5825–5829
Wiseman RW, Miller EC, Miller JA, Liem A (1987) Structure-activity studies of the hepatocarcinogenicities of alkenylbenzene derivatives related to estragole and safrole on administration to preweanling male C57BL/6J × C3H/HeJ F1 mice. Cancer Res 47: 2275–2283
Wogan GN (1976) The induction of liver cancer by chemicals. In: Linsell DA, Warwick GP (eds) Liver cell cancer. Elsevier, New York, pp 121–150
Wong JJ, Hsieh DPH (1976) Mutagenicity of aflatoxins related to their metabolism and carcinogenic potential. Proc Natl Acad Sci USA 73: 2241–2244
Yeh FS, Mo CC, Yen RC (1985) Risk factors for hepatocellular carcinoma in Guangxi, People’s Republic of China. Nat Cancer Inst Monogr 69: 47–48
Zedeck MS (1984) Hydrazine derivatives, azo and azoxy compounds, and methylazoxymethanol and cycasin. In: Searle CE (ed) Chemical carcinogens, 2nd edn. American Chemical Society, New York, pp 915–944
Zhu JQ, Zhang LS, Hu X, Xiao Y, Chen JS, Xu YC, Fremy J, Chu FS (1987) Correlation of dietary aflatoxin B1 levels with excretion of aflatoxin M1 in human urine. Cancer Res 47: 1848–1852
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1990 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Groopman, J.D., Cain, L.G. (1990). Interactions of Fungal and Plant Toxins with DNA: Aflatoxins, Sterigmatocystin, Safrole, Cycasin, and Pyrrolizidine Alkaloids. In: Cooper, C.S., Grover, P.L. (eds) Chemical Carcinogenesis and Mutagenesis I. Handbook of Experimental Pharmacology, vol 94 / 1. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-74775-5_10
Download citation
DOI: https://doi.org/10.1007/978-3-642-74775-5_10
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-74777-9
Online ISBN: 978-3-642-74775-5
eBook Packages: Springer Book Archive